| 摘要 |
#CMT# #/CMT# Use of dimethylaminoethanol (I) in free-form, its salts or esters and hydrates and solvates, for the preparation of medicaments for the treatment of a non dementia mild cognitive impairment, is claimed. #CMT#ACTIVITY : #/CMT# Nootropic. #CMT#MECHANISM OF ACTION : #/CMT# None given. No biological data given. #CMT#USE : #/CMT# (I) is useful for the preparation of the medicaments for the treatment of non dementia mild cognitive impairment, for treatment of benign mnestic decline, to treat hippocampal amnesic syndrome, to treat a moderate cognitive alteration corresponding to 0.5 stage of clinical dementia rating. #CMT#ORGANIC CHEMISTRY : #/CMT# Preferred Components: (I) is used in the form of a salt or ester comprising a derivatives of pyroglutamate, hydrochloride, ascorbate, bitartrate, dihydrogen phosphate, orotate, succinate, carbamate, phenylactate, benzoate, para-acetamido benzoate and aceglutamide, preferably deanol pyroglutamate. The medicament is present in the unit dosage form for administration by daily oral administration of (I) leading to a plasma rate corresponding to concentration maximum (C m a x) of 1.5 mu g/ml of (I). The medicament is presented in the form of unit dosage for administration by daily oral dosage of pyroglutamate of dimethylaminoethanol leading to a plasma rate corresponding to a C m a x of 1.5 mu g/ml of (I) and a plasma rate corresponding to a C m a x of 24 ng/ml of pyroglutamic acid. #CMT#ADMINISTRATION : #/CMT# Administration of (I) is 300 mg-3 g per unit, preferably 1500 mg, orally (claimed). |
